Screener
Syndax Pharmaceuticals SNDX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-197154
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized; 88,543,881 and 87,405,979 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 9 | 9 |
| Additional paid-in capital | 1,590,855 | 1,570,749 |
| Accumulated other comprehensive gain | 11 | 452 |
| Accumulated deficit | (1,549,253) | (1,506,580) |
| Total stockholders’ equity | 41,622 | 64,630 |
Item 1: Financial Statements
FAQ
- What is Syndax Pharmaceuticals's common stock?
- Syndax Pharmaceuticals (SNDX) reported common stock of $9K in Q1 2026.
- How has Syndax Pharmaceuticals's common stock changed year-over-year?
- Syndax Pharmaceuticals's common stock decreased by 0.0% year-over-year, from $9K to $9K.
- What is the long-term trend for Syndax Pharmaceuticals's common stock?
- Over 5 years (2020 to 2025), Syndax Pharmaceuticals's common stock has grown at a 12.5% compound annual growth rate (CAGR), from $5K to $9K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Syndax Pharmaceuticals's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude